Objective: Menopausal symptoms such as hot flashes and night sweats may persist for 10 to 20 years or even longer. Information about the extent to which older women use hormone therapy is limited. The aim of this study was to determine the use of hormone therapy in Swedish women aged 80 years or older.
C ross-sectional and prospective studies have shown that 50% to 75% of women in the western world report vasomotor symptoms, such as hot flashes and night sweats, when going through menopause. 1<3 These symptoms often cause discomfort and may negatively affect daytime activities, sleep, and quality of life. Besides hot flashes and night sweats, vaginal dryness and dyspareunia are the only symptoms that have been proven to be associated with endocrine changes around menopause. 1<4 Hot flashes are often described as transient symptoms, but they may actually persist for many years; the median time is about 5 years, and around 20% of women still report vasomotor symptoms 10 to 20 years after menopause. 1, 5 The Heart and Estrogen/Progestin Replacement Study found that, in a sample of women with a mean age of 67 years, about every sixth woman reported very frequent or frequent hot flashes at baseline. 6 Furthermore, one of four women reported vaginal dryness at baseline. Younger women reported being troubled by hot flashes and vaginal dryness more frequently than older women. However, almost 20% of women aged 70 to 74 years reported very frequent or frequent hot flashes. 6 In one longitudinal study, premenopausal and postmenopausal women were followed from the 1960s to the 1990s. Approximately 9% of the 72-year-old women (4 of 47) reported being troubled by hot flashes. 7 There are few published studies of menopausal symptoms in women older than 80 years. We have, however, reported that 22% of 184 women aged 85 years either used hormone therapy (HT) or reported hot flashes (16%) at least several times per week. 8 The use of HT increased gradually from the 1980s; however, after reports of increased risks of mainly cardiovascular disease and breast cancer, 9 the use of HT decreased dramatically. 10<12 Most national and international recommendations were changed; in Sweden, HT was recommended only for women with moderate or severe vasomotor symptoms, at the lowest possible doses, and for the shortest possible time. 13 Recently, it has been shown that HT initiated shortly after menopause seems to induce low cardiovascular risks and only a very small risk or no risk of breast cancer especially if no progestagen is added. 14 On the other hand, the risks of adverse effects and cardiovascular events seem to increase the longer the time interval between menopause and start of treatment. At least in Sweden, HT still seems to be controversial even among early postmenopausal women because only about 6% of women aged 47 to 56 years use HT, according to data from the Swedish Prescribed Drug Register 2010-2012. Fear of HT is probably still present; thus, many women experiencing hot flashes are deprived successful treatment. 12 On the other hand, low-dose estrogen therapy administered locally for urogenital symptoms has very few adverse effects and should not have been affected by reports on HT risks.
In Sweden, there is a uniquely long history of creating national registers that provide unique data on the entire population. Personal identity number (PIN) was introduced in 1947, making it possible to maintain national records on the entire population. Since 1991, the National Tax Board has been responsible for maintaining the Swedish PIN-based registry. 15 The Swedish Prescribed Drug Register at the National Board of Health and Welfare contains information on all prescribed drugs dispensed at pharmacies in Sweden. 16 Thus, data on dispensed drugs actually provided by pharmacies to individualsVbut not the written prescriptions (which, in reality, may not have been used by the individuals)Vare kept in the register. The register was established in 1999; since July 2005, the full PIN has been included in every entry. The register covers the entire population in the country, and the PIN is missing for less than 0.3% of all dispensations. Demographic and socioeconomic data on inhabitants are registered yearly at Statistics Sweden, and these data can be linked by the PIN to the Swedish Prescribed Drug Register.
Our study is a strictly descriptive epidemiological study linking registers from the National Board of Health and Welfare and Statistics Sweden. The aim of this study was to determine the prevalence and incidence of HT users and the use of local estrogen therapy in women aged 80 years or older. We also wanted to determine the duration of HT use among incident HT users 80 years or older and living in Sweden across a period of 5 years (April 2006 to December 2011). Another aim was to determine clinical specialties among physicians initiating and continuing HT prescription for older women.
METHODS
The study group consists of all women, nationally registered in Sweden, who were aged at least 40 years on December 31, 2005. These women were followed from July 1, 2005 until December 31, 2011. Drugs for systemic HT for climacteric symptoms were defined as oral and transdermal products within Anatomical Therapeutic Chemical classification groups: G03CA03 estradiol (excluding low-dose products and drugs for local vaginal treatment), G03CA57 conjugated estrogens, G03CX01 tibolone, G03FA01 norethisterone and estrogen, G03FA12 medroxyprogesterone and estrogen, G03FA15 dienogest and estrogen, G03FA17 drospirenone and estrogen, G03FB05 norethisterone and estrogen, G03FB06 medroxyprogesterone and estrogen, and G03FB09 levonorgestrel and estrogen. No injectable preparations are used for HT in Sweden. Drugs for low oral or local vaginal treatment were defined as low-dose estradiol in vaginal tablets or estriol in vagitories, crème, or a locally applied vaginal ring or low-dose oral estriol within G03CA03 estradiol and G03CA04 estriol, respectively. Data on dispensed drugs from the Swedish Prescribed Drug Register were extracted by the National Board of Health and Welfare and linked to demographic and socioeconomic data from Statistics Sweden. Data on education, country of birth, living arrangements, employment status, civil status, and income were studied on one occasion during the study period (December 31, 2005) .
The Swedish Prescribed Drug Register contains information on the prescribers' specialties, in chronological order. The latest registered specialty was used to define the main specialty of each prescriber.
Current users versus new users of HT
Data from the Swedish Prescribed Drug Register connected to PIN are available from July 1, 2005. In Sweden, HT can only be dispensed for 3 months at a time, but prescriptions can include four 3-month periods and thus be for one full year. To define new (incident) users of HT, we used a preceding washout period of 9 months (274 d) without any dispensation. This corresponds to approximately at least 6 months without treatment because the maximal allowed time covered by a dispensation in Sweden is 3 months. A new user is hence defined as a woman who had been dispensed HT at least once between April 1, 2006 and December 31, 2006, but not during the washout period from July 1, 2005 to March 31, 2006.
All new users were followed across the full study period (ie, from the time of the first dispensation on April 1, 2006 or later until December 31, 2011). The duration of treatment was calculated as the time from the first day until 120 days after the last dispensation. For women on unit dose dispensed drugs, the duration was calculated as the time until 14 days after the last dispensation because unit dose drugs are dispensed every 14 days. The longest time interval between dispensations that was not considered a discontinuation was approximately 9 months (273 d).
A current (prevalent) user is defined as a woman who had been dispensed HT at least once during the period starting from July 1, 2005 to March 31, 2006 (ie, during the 274-d washout period).
Statistics
All data from the National Board of Health and Welfare were delivered on Excel files. Data were exported and analyzed by SAS version 9.3 (SAS Institute, Cary, NC). Persistence of treatment was calculated by Kaplan-Meier survival analysis, determining the time of discontinuation for each woman. Women were excluded from further analysis (censored) in the event of death or end of follow-up. Descriptive statistical methods were used.
Missing data for each variable were handled as lost data.
Ethics
Data from the Swedish Prescribed Drug Register and Statistics Sweden were extracted and pseudonymized by the National Board of Health and Welfare. Data protection and encoding were carried out by the National Board of Health and Welfare for at least 3 years. The protocol for this study was approved by the Regional Ethical Review Board in Linköping, Sweden (D-nr 2012/386-31).
RESULTS
All 310,923 Swedish women aged at least 80 years on December 31, 2005 constituted our cohort. Of these women, 609 (0.2%) became new HT users during the study period. Another 2,361 women (0.8%) were defined as current HT users during the first 9 months of the study period. Of these, 1,703 women (0.5%) had three or more dispensations during the study period ( Table 1) .
The median duration of HT use in new users aged 80 years or older was 257 days (25th to 75th percentiles, 611-120 d), whereas new users aged 40 to 79 years had a median HT duration of 488 days (25th to 75th percentiles, 1,226-177 d), as illustrated in the Kaplan-Meier diagram in Figure. The mean number of days of treatment was 378 days for new users aged 80 years or older and 539 days for women aged 40 to 79 years.
About one in six women aged 80 years or older had been dispensed local vaginal estrogen therapy for at least four 3-month periods ( Table 2) .
HT use was mainly initiated by gynecologists and general practitioners, but some geriatricians also prescribed HT use (Table 3 ). Repeated prescriptions tended to be issued to a somewhat higher degree by general practitioners (from 36.8% to 42.5% of the prescribers).
When new HT use and current HT use were analyzed against demographic and socioeconomic data, no specific variables (education, country of birth, place of residence [four categories], civil status, and income) correlated with use or nonuse of HT or with duration of HT use.
DISCUSSION
Although climacteric symptoms are often claimed to be symptoms of short duration (mean, 5 y), our data from Swedish registers show that many women older than 80 years are still prescribed and dispensed HT. We also found that a number of women older than 80 years were incident users (ie, had been prescribed and dispensed HT after the previously defined Bwashout[ period of at least 9 mo, during which they neither received nor used HT). However, they may not be true new users because they could have been treated earlier in life before the start of the study period.
In general, medical product agencies and specialist associations recommend that HT be used only for more troublesome vasomotor symptoms at the lowest possible dose for the shortest time possible. Our finding that numerous Swedish women use HT after the age of 80 years shows that doctors do not always follow these recommendations. Even a number of women older than 80 years were new users of HT at least during the study period (ie, they were dispensed HT after at least 6 mo without treatment).
We can only speculate about the reasons for prescribing HT to this old age group. In a previous study on 85-year-old women, 16% of them reported hot flashes at least several times per week 8 (ie, there may still be a need for HT in a small group of older women). Furthermore, some of the women may experience osteoporosis and prefer HT before other treatment options. However, HT is not the first-line therapy for osteoporosis in Sweden to date. A French study found that, after 2002, HT tended to be prescribed more often for hot flashes than for other reasons, and that less than one third of prescriptions were written for reasons not linked to hot flashes. 17 Before 2002, prescriptions written for other reasons were more common. 16 Although we have no data on the indications for the prescriptions, probably many of the women aged 80 years or older who had been prescribed HT still had flashes that they wanted to relieve. The fact that a number of women had been prescribed and dispensed HT after at least 6 months without treatment suggests that these women either were true new users or had earlier used HT that they had tried to wean off. After some time without therapy, they may have decided to start again (eg, for reasons such as impaired well-being, hot flashes, and/or sleep disturbances). We have previously found that impaired psychological well-beingVnot the mere number of hot flashesVwas the strongest predictor for restarting therapy after discontinuing HT. 18 It could be argued that the register data on HT included dispensation of local estrogens for symptoms of urogenital atrophy. However, the database clearly separates these low doses of oral or vaginal preparations from HT. We also analyzed these data and found that about every sixth woman older than 80 years had been dispensed estrogens for treatment of local urogenital symptoms. This is not surprising because such symptoms are reported to be very prevalent and to occur in almost every other woman after menopause 1, 5 ; and treatment has to be ongoing to be effective.
CONCLUSIONS
A substantial number of Swedish women aged 80 years or older still use HT, probably (at least for some of them) for vasomotor symptoms, and a number of women are prescribed and dispensed HT after not having used it for at least 6 months.
Thus, issues of climacteric symptoms, besides symptoms of urogenital atrophy, should not be forgotten when counseling women around and after age 80 years. 
